The latest update is out from DiagnaMed Holdings Corp. ( (TSE:DMED) ).
DiagnaMed Holdings Corp. has been granted Orphan Drug Designation by the FDA for its use of molecular hydrogen in treating amyotrophic lateral sclerosis (ALS), marking a significant step forward in rare disease research. This designation not only highlights the potential of molecular hydrogen as a novel therapeutic option for ALS but also provides DiagnaMed with incentives such as tax credits and market exclusivity, enhancing its ability to accelerate development programs. Additionally, DiagnaMed has entered into a non-binding letter of intent with Revive Therapeutics to potentially acquire full rights to its intellectual property related to molecular hydrogen for ALS, aiming to advance treatment options for the ALS community.
More about DiagnaMed Holdings Corp.
DiagnaMed Holdings Corp. is a leading provider of innovative technology solutions in the hydrogen and life sciences industries. The company focuses on unlocking the medical potential of molecular hydrogen for neurodegenerative diseases and brain health conditions.
YTD Price Performance: -14.29%
Average Trading Volume: 200,820
Technical Sentiment Consensus Rating: Hold
Find detailed analytics on DMED stock on TipRanks’ Stock Analysis page.